Peter Ellmark - Department of Immunotechnology;Lund University;Department of Immunotechnology, Lund University

基本信息

浏览量：26

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 103 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

ATOR-4066, a Neo-X-Prime™ Bispecific Antibody Targeting CD40 and CEACAM5, Induces Tumor Localized Immune Cell Activation in Preclinical in Vivo Tumor Model

Hampus Andersson, Ida Uddback,Mona Celander,Maria Johansson,Lill Ljung,Anneli Nilsson, Amulya Krishna Shetty,David Gomez Jimenez,Mattias Levin,Sara Fritzell,Laura von Schantz,Malin Lindstedt,Karin Hagerbrand,Anette Sundstedt,Peter Ellmark

CANCER RESEARCHno. 6 (2024)

引用0浏览0引用

Abstract 5309: ATOR-4066, a Neo-X-Prime™ Bispecific Antibody Targeting CD40 and CEACAM5, Induces Tumor Localized Immune Cell Activation in Preclinical in Vivo Tumor Model

Hampus Andersson, Ida Uddbäck,Mona Celander,Maria Johansson,Lill Ljung,Anneli Nilsson, Amulya Krishna Shetty,David Gomez Jimenez,Mattias Levin,Sara Fritzell,Laura von Schantz,Malin Lindstedt,Karin Hägerbrand,Anette Sundstedt,Peter Ellmark

Cancer Researchno. 6_Supplement (2024): 5309-5309

引用0浏览0引用

Interim pharmacodynamic analyses of mitazalimab in combination with FOLFIRINOX in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) identify CD4 effector T cells as a correlate of treatment outcomes

Max M. Wattenberg,Karin Enell Smith,Yago Pico de Coana,David Gomez Jimenez,Malin Carlsson,Sumeet Vijay Ambarkhane,Peter Ellmark, Gregory L. Beatty

CANCER RESEARCHno. 2 (2024)

引用0浏览0引用

Abstract 2376: Mitazalimab, a Potent CD40 Agonist in Combination with FOLFIRINOX Demonstrates Changes Consistent with Increased Immune Activation in TME and Peripheral Blood in a Preclinical Pancreatic Cancer Tumor Model

Karin Enell Smith,David Gomez Jimenez,Mia Thagesson,Anneli Nilsson,Yago Pico de Coaña,Sumeet Ambarkhane,Peter Ellmark

Cancer Researchno. 6_Supplement (2024): 2376-2376

引用0浏览0引用

CD4 Effector T Cell Expansion to Identify Objective Responses to the CD40 Agonist Mitazalimab in Combination with Modified FOLFIRINOX (mffx) As First-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma (mpdac) in the OPTIMIZE-1 Study

Max Miller Wattenberg,Karin Enell Smith,Yago Pico de Coana,David Gomez Jimenez,Sumeet Vijay Ambarkhane,Peter Ellmark,Gregory Lawrence Beatty

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2024)

引用0浏览0引用

Combining CD40 Agonist Mitazalimab with Mfolfirinox in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (OPTIMIZE-1): a Single-Arm, Multicentre Phase 1b/2 Study

Jean -Luc Van Laethem,Ivan Borbath,Hans Prenen,Karen Paula Geboes,Aurelien Lambert,Emmanuel Mitry,Philippe Alexandre Cassier,Jean-Frederic Blanc,Lorenzo Pilla,Jaime Feliu Batlle,Mercedes Rodriguez Garrote, Roberto Antonio Pazo-Cid,Inmaculada Gallego,Karin Enell Smith,Peter Ellmark,Yago Pico de Coana,Sumeet Vijay Ambarkhane,Teresa Macarulla

The Lancet Oncologyno. 7 (2024): 853-864

引用0浏览0WOS引用

Next-generation CD40 agonists for cancer immunotherapy

Hampus Andersson,Barnabas Nyesiga, Tova Hermodsson,Karin Enell Smith,Karin Hagerbrand,Malin Lindstedt,Peter Ellmark

EXPERT OPINION ON BIOLOGICAL THERAPYno. 5 (2024): 351-363

引用0浏览0WOS引用

Distinct Infiltration of T Cell Populations in Bladder Cancer Molecular Subtypes

Viktor Sincic, Ken F. Arlenhold, Sarah Richtmann,Henrik Lilljebjoern,Pontus Eriksson,Gottfrid Sjoedahl, Mats Wokander,Karin Haegerbrand,Peter Ellmark,Thoas Fioretos,Carl A. K. Borrebaeck,Fredrik Liedberg,Kristina Lundberg

CELLS（2024）

引用0浏览0WOS引用

ATOR-4066, a Neo-X-Prime Bispecific Antibody Targeting CD40 and CEA, Activates Myeloid Cells in Primary Human Tumors in Vitro and Induces Anti-Tumor Immunity in Vivo

Karin Hagerbrand,Anette Sundstedt,Mattias Levin,Yago Pico de Coana,Laura Varas,Lill Ljung,Anneli Nilsson,Mona Celander,David Gomez Jimenez,Hampus Andersson,Malin Lindstedt,Peter Ellmark

CANCER RESEARCHno. 7 (2023)

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn